Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical cannabidiol and palmitoylethanolamide for osteoarthritis pain
ACTRN12622000723785Phase 2Not yet recruiting
- Sponsor
- Westmead Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoarthritis (OA) comparing Cannabidiol sequence arm, Palmitoylethanolamide sequence arm and Placebo sequence arm (3 arms). Primary endpoints: Stage 1 cannabidiol pharmacokinetic profile, Stage 2 analgesic efficacy and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
cannabidiolpalmitoylethanolamide
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12622000723785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000723785.